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Salmonella spp. producing extended-spectrum beta-lactamases (ESBLs) have been reported in many coun-
tries, but there is no information on their prevalence in Africa. ESBL-producing Salmonella enterica serotype
Isangi and S. enterica serotype Typhimurium strains have been noted in South Africa since 2001. A total of 160
consecutive isolates of Salmonella spp. were collected from 13 hospitals located in different cities in South
Africa over a 5-month period from December 2002 to April 2003. All strains were screened for production of
ESBLs by the double disk diffusion test and for AmpC production by assessing resistance to cefoxitin. blaSHV,
blaTEM, blaCTX-M, and blaCMY-2 were sought from all ESBL-positive and cefoxitin-resistant isolates. A total of
15.6% (25 of 160) isolates produced SHV or TEM ESBLs, and 1.9% (3 of 160) produced CMY-2. Nine S. enterica
serotype Typhimurium, eight S. enterica serotype Isangi, and three S. enterica serotype Muenchen strains
produced either TEM-63 or a derivative of TEM-63 designated TEM-131. Both TEM-63 and TEM-131 have an
isoelectric point of 5.6, and their sequences have the following amino acid substitutions compared to the TEM-1
sequence: Leu21Phe, Glu104Lys, Arg164Ser, and Met182Thr. Additionally, TEM-131 has an Ala237Thr sub-
stitution. ESBL-producing Salmonella spp. have become a significant public health problem in South Africa
with particular implications for the treatment of serious nontyphoidal Salmonella infections in children, for
whom extended-spectrum cephalosporins were the preferred treatment.
Resistance to the extended-spectrum cephalosporins among
members of the family Enterobacteriaceae has become a grow-
ing worldwide problem subsequent to the occurrence of ex-
tended-spectrum beta-lactamases (ESBLs) and AmpC-type
beta-lactamases (9). Although reports of ESBLs associated
with Salmonella spp. are relatively rare compared to those for
other species in the family Enterobacteriaceae, the number of
reported cases in this organism has been increasing in recent
years. Salmonellae have been found to express a wide variety
of ESBL types, including TEM, SHV, PER, OXA, and CTX-M
enzymes (1, 6, 10, 12, 21, 39, 44). Additionally, Salmonella
strains have been detected which produce plasmid-mediated
AmpC-type beta-lactamases (21, 35, 38).
The advent of ESBLs and AmpC beta-lactamases in Salmo-
nella species is of considerable therapeutic importance, especially
in developing nations where infections with these organisms are
numerous. Resistance to ampicillin, trimethoprim-sulfamethox-
azole, and chloramphenicol is now exceedingly common, ne-
cessitating use of fluoroquinolones or extended-spectrum
cephalosporins as treatment of extraintestinal infections (13).
Widespread fluoroquinolone use in children has been discour-
aged because of the potential adverse effects on cartilage de-
velopment. Therefore, extended-spectrum cephalosporins (es-
pecially cefotaxime or ceftriaxone) are the mainstay of
treatment of serious infections due to nontyphoidal Salmonella
spp. in children. The production of ESBLs or AmpC beta-
lactamases consequently has considerable implications for clin-
ical microbiology laboratories and physicians in areas in which
infections with nontyphoidal Salmonella spp. are common.
ESBLs have been found in many enterobacterial species in
South Africa (7, 14, 22, 36). Since 2000, the Enteric Diseases
Reference Unit of the National Institute for Communicable
Diseases in South Africa has noted increasing numbers of
nontyphoidal Salmonella isolates, particularly S. enterica sero-
type Typhimurium and S. enterica serotype Isangi, with positive
screening tests for ESBLs. The aim of this study was to deter-
mine the genetic basis for antibiotic resistance in these isolates
and to briefly describe the epidemiology of infections with
these organisms.
MATERIALS AND METHODS
Bacterial strains. Salmonella isolates of human origin are sent to the Enteric
Diseases Reference Unit of the National Institute for Communicable Diseases in
Johannesburg, South Africa, from clinical microbiology laboratories across the
country as part of national surveillance for enteric pathogens. A total of 160
consecutive Salmonella isolates arriving in this laboratory, collected from thir-
teen different hospitals in South Africa between December 2002 and March
2003, were selected for further analysis. The identification of the isolates as being
of Salmonella species was confirmed at the Enteric Diseases Reference Unit by
conventional biochemical tests. Serotyping of all isolates was performed, using
the method of slide agglutination on the basis of lipopolysaccharide (O) and
flagellar (H) antigens and commercially available antisera (Bio-Rad, Marnes-la-
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Coquette, France), according to the Kauffman-White scheme for Salmonella
serotyping (25, 37). Double disk diffusion testing was performed according to the
method of Jarlier et al. (23), with ceftriaxone, cefotaxime, ceftazidime, and
aztreonam disks 30 mm (center to center) away from a disk containing amoxi-
cillin-clavulanic acid. Further analysis of the isolates was undertaken in Pitts-
burgh and Cleveland.
Antibiotic susceptibility. Susceptibility tests were performed using the Kirby-
Bauer disk diffusion method and following NCCLS guidelines (32). Antimicro-
bials used were ampicillin, aztreonam, cefixime, cefepime, cefoxitin, cefotaxime,
cefpodoxime, ceftazidime, ceftriaxone, amoxicillin-clavulanic acid, ertapenem,
imipenem, meropenem, norfloxacin, nalidixic acid, ofloxacin, levofloxacin, gati-
floxacin, ciprofloxacin, moxifloxacin, tetracycline, chloramphenicol, streptomy-
cin, and trimethoprim-sulfamethoxazole.
The MICs of cefotaxime, cefotaxime plus clavulanic acid, ceftazidime, cefta-
zidime plus clavulanic acid, cefepime, cefoxitin, nalidixic acid, ciprofloxacin,
trimethoprim-sulfamethoxazole, imipenem, and meropenem were determined by
E-test for strains with positive double disk diffusion tests (as an indicator of
ESBL production) or cefoxitin resistance (as an indicator of possible plasmid-
mediated AmpC beta-lactamases). The strips were used according to the man-
ufacturer’s instructions (AB Biodisk, Solna, Sweden).
Escherichia coli ATCC 25922 was used as the reference strain for antimicrobial
susceptibility testing (32).
IEF. Analytical isoelectric focusing (IEF) was performed in duplicate on all
isolates with positive double disk diffusion test results or cefoxitin resistance by
the use of methods that have been previously described (34). Enzyme activity was
detected by placing filter paper soaked in nitrocefin (Becton Dickinson, Sparks,
Md.) (500 g/ml) over the focused gel.
PFGE. Pulsed field gel electrophoresis (PFGE) analysis was performed ac-
cording to the Centers for Disease Control and Prevention PulseNet protocol
(41). Briefly, genomic DNA was isolated and digested with XbaI (New England
Biolabs, Beverly, Mass.). PFGE was performed with a CHEF III system (Bio-
Rad, Hercules, Calif.) and the following run parameters: for block I, a switch
time of 3 to 65 s and a run time of 17 h; for block II, a switch time of 15 to 30 s
and a run time of 6 h. Dendrograms were created with Molecular Analyst
(Bio-Rad) by using the Dice coefficient, unweighted pair group method with
arithmetic means (UPGMA), and a position tolerance of 1.3%. Relatedness of
the isolates was also determined by the criteria of Tenover et al. (42).
Plasmid profiles. Plasmids were extracted and electrophoresed by the method
of Kado and Liu (24). Transformation assays were performed by electroporation
(Gene Pulser; Bio-Rad) with E. coli strain DH10B (Bio-Rad) as the recipient.
Transformants were cultivated on nutrient agar containing ampicillin (100 g/
ml).
PCR screening. A 10-l aliquot of an overnight culture of the test isolate was
diluted 1:10 with water and boiled for 15 min. PCR amplification was then
performed with 10 l of this dilution as the DNA template. The primer sets are
shown in Table 1. Four primer pairs were used: blaTEM-1 (14), blaSHV-1 (14),
blaCTX-M (8), and blaCMY-2 (33, 34). PCR conditions were as previously de-
scribed (8, 14, 33).
Sequencing. The primers used for DNA sequencing are shown in Table 1.
Numbering follows the scheme of Ambler et al. (3). The nucleotide sequences of
the amplified products were determined using ABI3700 and ABI3100 genetic
analyzers at a core facility at the University of Pittsburgh. Data collection and
analysis were performed using Lasergene DNASTAR sequencing analysis soft-
ware.
Nucleotide sequence accession number. The DNA sequence and deduced
amino acid sequence of TEM-131, the novel beta-lactamase, has been deposited
in GenBank and assigned accession number AY436361.
RESULTS
Epidemiology. From 1999 to 2003, the Enteric Diseases Ref-
erence Unit of the National Institute for Communicable Dis-
eases in the Republic of South Africa received annually, from
all provinces of the country, between 500 and 1,500 nontyphoi-
dal Salmonella strains for serotyping. Prior to 2000, S. enterica
serotype Isangi was a rare isolate, but in 2002 was second only
to S. enterica serotype Typhimurium in frequency of isolates
TABLE 1. Nucleotide sequences of the oligonucleotides used for amplification and sequencing
Primer (reference)a Sequence (5–3) Nucleotidepositions
Expected size of
amplification
product (bp)
blaTEM (15)
Amplification and sequencing
TEM-1 (F) ATGAGTATTCAACATTTCCGTG 1–22
TEM-4 (R) TTACCAATGCTTAATCAGTGAG 861–840 840
Sequencing
TEM-2 (R) TTCTGTGACTGGTGAGTACT 324–305
TEM-3 (R) GAGTAAGTAGTTCGCCAGTT 595–576
blaSHV (15)
Amplification and sequencing
SHV-1 (F) ATGCGTTATATTCGCCTGTG 1–20 846
SHV-3 (R) GTTAGCGTTGCCAGTGCTCG 865–846
Sequencing
SHV-2 (R) CGTTTCCCAGCGGTCAAGG 489–471
blaCTX-M (7)
Amplification
CTX-MA CGCTTTGCGATGTGCAG 264–280 550
CTX-MB ACCGCGATATCGTTGGT 814–798
blaCMY-2 (36)
Amplification and sequencing
Amp3 (F) ATGATGAAAAAATCGTTATGCTGC 1924–1947 1,145
Amp2 (R) TTATTGCAGCTTTTCAAGAATGCGCCA 3069–3043
Sequencing
Amp (F) ATAACCACCCAGTCACGC 2132–2149
Amp (R) CAGTAGCGAGACTGCGCA 2762–2745
a F, forward primers; R, reverse primers.
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received by the Enteric Diseases Reference Unit. In 2002, S.
enterica serotype Isangi accounted for approximately 20% of
all isolates received. Furthermore, the majority of S. enterica
serotype Isangi isolates were found to have positive double
disk diffusion test results, implying the presence of ESBLs.
Since 2000, isolates of other serotypes (most notably S. enterica
serotype Typhimurium) have also been found to produce
ESBLs.
Strains. A total of 160 consecutive Salmonella isolates from
the Enteric Diseases Reference Unit, National Institute for
Communicable Diseases, South Africa, were selected for fur-
ther analysis. These isolates were collected from 13 hospitals in
South Africa from December 2002 to March 2003. The sources
of the isolates were blood cultures (94 isolates), feces (48
isolates), urine (8 cultures), pleural fluid (3 isolates), cerebro-
spinal fluid (1 isolate), pericardial fluid (1 isolate), and miscel-
laneous (5 isolates). The serotypes of the strains were as fol-
lows: 115 S. enterica serotype Typhimurium, 14 S. enterica
serotype Enteritidis, 10 S. enterica serotype Isangi, 6 S. enterica
serotype Dublin, 5 S. enterica serotype Muenchen, 3 S. enterica
serotype Hadar, 2 S. enterica serotype Newport, and 1 each of
S. enterica serotype Anatum, S. enterica serotype Bovismorbifi-
cans, S. enterica serotype Infantis, S. enterica serotype Molade,
and S. enterica serotype Schwarzengrund. A total of 25 (15.6%)
isolates (14 S. enterica serotype Typhimurium, 8 S. enterica
serotype Isangi, and 3 S. enterica serotype Muenchen) were
screen positive for ESBL production. Two S. enterica serotype
Typhimurium and the one S. enterica serotype Schwarzengrund
were cefoxitin resistant. For purposes of further epidemiologic
analysis, a further 23 S. enterica isolates of serotypes Typhi-
murium, Isangi, and Muenchen which were ampicillin resistant
but not screen positive for ESBL production or cefoxitin re-
sistant were chosen for further analysis.
IEF. Each strain which was screen positive for ESBL pro-
duction or which was cefoxitin resistant produced one or two
beta-lactamases with pI values of 5.4, 5.6, 8.2, and greater than
TABLE 2. Molecular epidemiology of ESBL- and non-ESBL-producing isolates of S. enterica serotype Typhimurium, S. enterica serotype
Isangi, S. enterica serotype Muenchen, and S. enterica serotype Schwarzengrund
S. enterica strain and
isolate no. PFGE type
Isoelectric
point(s) Beta-lactamase(s) Location of origin
Serotype Typhimurium
1 A1 5.4, 8.2 TEM-1, SHV-12 Gauteng (hospital 1)
2 A1 5.4, 8.2 TEM-1, SHV-12 Eastern Cape (hospital 5)
3 A1 5.4, 8.2 TEM-1, SHV-12 Gauteng (hospital 2)
4 A2 5.4, 8.2 TEM-1, SHV-12 Gauteng (hospital 1)
5 A2 5.4, 8.2 TEM-1, SHV-12 Gauteng (hospital 3)
6 A3 5.6 TEM-131 Gauteng (hospital 1)
7 A3 5.6 TEM-131 Gauteng (hospital 1)
8–13 A3 5.6, 8.2 TEM-131, SHV-5 Freestate (hospital 7)
14 A3 5.4 TEM-1 Gauteng (hospital 1)
15 A4 5.6, 8.2 TEM-131, SHV-5 Freestate (hospital 7)
16–19 A5 5.4 TEM-1 Gauteng (hospital 3)
20, 21 A5 5.4 TEM-1 Eastern Cape (hospital 5)
22 A5 5.4 TEM-1 Western Cape (hospital 8)
23–26 A6 5.4 TEM-1 Gauteng (hospital 2)
27 A7 5.4 TEM-1 Gauteng (hospital 1)
28 A8 5.4 TEM-1 Gauteng (hospital 1)
29 A9 5.4 TEM-1 Gauteng (hospital 3)
30 B 8.2 CMY-2 Western Cape (hospital 8)
31 C1 8.2 CMY-2 Gauteng (hospital 2)
32 C2 5.4 TEM-1 Freestate (hospital 7)
33 L 5.4 TEM-1 Freestate (hospital 7)
34 N 5.4 TEM-1 Gauteng (hospital 2)
35 K 5.4 TEM-1 Gauteng (hospital 4)
Serotype Isangi
36 D1 5.6 TEM-63 Gauteng (hospital 3)
37 D2 5.6 TEM-63 Gauteng (hospital 2)
38–41 D3 5.6 TEM-63 Gauteng (hospital 2)
42 E 5.6 TEM-131 Gauteng (hospital 2)
43 F 5.6, 8.2 TEM-131, SHV-5 Gauteng (hospital 3)
44 M 5.4 TEM-1 Gauteng (hospital 4)
45 P 5.4 TEM-1 Gauteng (hospital 2)
Serotype Muenchen
46 G 5.6 TEM-63 Eastern Cape (hospital 6)
47–48 G 5.6 TEM-63 Eastern Cape (hospital 5)
49 R 5.4 TEM-1 Western Cape (hospital 8)
50 S 5.4 TEM-1 Gauteng (hospital 1)
Serotype Schwarzengrund
51 H 8.2 CMY-2 Gauteng (hospital 3)
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8.2 in various combinations (Table 2). Beta-lactamase enzymes
with pI values in the range of 5.4 to 5.6 (consistent with the pI
range of TEM enzymes) were identified in all isolates screen
positive for ESBLs. Enzymes with a pI value of 8.2 (consistent
with the pI range of SHV enzymes) were detected in 12 S.
enterica serotype Typhimurium and 1 S. enterica serotype
Isangi isolate. Two S. enterica serotype Typhimurium and the
one S. enterica serotype Schwarzengrund that produced beta-
lactamase enzymes with cefoxitin resistance had pI values
greater than 8.2 (consistent with the pI range of AmpC-like
beta-lactamases). More than one beta-lactamase was identified
in 12 S. enterica serotype Typhimurium and 1 S. enterica sero-
type Isangi strains.
Electroporation and plasmid analysis. Large (10-kb) plas-
mids were isolated from all the strains (data not shown). The
MICs of the transformants with different plasmids are shown in
Table 3.
PCR for detection of blaTEM, blaSHV, blaCTX-M, and blaCMY
resistance genes and sequencing results. blaTEM amplification
was achieved for all the isolates screen positive for ESBL
production. Thus, 14 S. enterica serotype Typhimurium iso-
lates, the 8 S. enterica serotype Isangi isolates, and the 3 S.
enterica serotype Muenchen isolates were found to have
blaTEM genes. Among the TEM-type ESBLs, TEM-63 and one
novel TEM-type, TEM-131, were identified. The amino acid
substitutions of the sequence of TEM-63 compared to the
TEM-1 beta-lactamase sequence were Leu21Phe, Glu104Lys,
Arg164Ser, and Met182Thr. The new TEM beta-lactamase
(TEM-131) differed from TEM-63 by a single substitution
(Ala237Thr) (Table 4). This protein has been designated
TEM-131 (http:www.lahey.org/studies/webt.htm).
Three S. enterica serotype Muenchen and six S. enterica
serotype Isangi isolates carried the gene for TEM-63, and two
S. enterica serotype Isangi and nine S. enterica serotype Typhi-
murium isolates carried the new TEM-131 gene (Table 2).
Seven S. enterica serotype Typhimurium strains and one S.
enterica serotype Isangi strain produced the SHV-5 enzyme,
and five S. enterica serotype Typhimurium strains produced the
SHV-12 enzyme. Under the experimental conditions in this
study, we were unable to detect any blaCTX-M genes. Of the
cefoxitin-resistant isolates, two S. enterica serotype Typhi-
murium and one S. enterica serotype Schwarzengrund carried
the CMY-2 gene.
Antibiotic susceptibility testing. Isolates producing TEM-
131 had ceftazidime MICs of 256 g/ml, cefotaxime MICs in
the range of 6 to 64 g/ml, and cefepime MICs in the range of
4 to 16 g/ml (Table 5). These ranges were also seen in the
transformant E. coli DH5 strains producing this enzyme (Ta-
ble 3). While the isolates producing TEM-63 also had ceftazi-
dime MICs  256 g/ml, the cefotaxime MICs were somewhat
lower than those observed with strains producing TEM-131
(cefotaxime MICs of 1.5 g/ml in the TEM-63–producing
transformant E. coli DH5 strain compared to 6 g/ml in the
TEM-131–producing strain) (Tables 3 and 5).
As expected, isolates producing CMY-2 had elevated MICs
for ceftazidime (range 198 to 256 g/ml), cefotaxime (32
g/ml), and cefoxitin (256 g/ml) while retaining suscepti-
bility to the carbapenems.
All but one of the ESBL-producing or CMY-2–producing
isolates were resistant to trimethoprim-sulfamethoxazole. All
isolates were resistant to chloramphenicol. Although no iso-
lates were ciprofloxacin resistant, all seven S. enterica serotype
Typhimurium isolates producing TEM-131 and SHV-5 and all
six S. enterica serotype Isangi isolates producing TEM-63 were
resistant to nalidixic acid. All isolates were susceptible to car-
bapenems.
PFGE. PFGE results of the S. enterica serotype Typhi-
murium isolates are presented in Table 2. A total of 29 isolates
of S. enterica serotype Typhimurium were possibly related by
PFGE (PFGE type A). These isolates were found in four
provinces (Gauteng, Eastern Cape, Free State, and Western
Cape). SHV-12–producing isolates which were indistinguish-
able from one another (PFGE type A1) were found in two
hospitals in Gauteng and a hospital in the Eastern Cape. These
hospitals are more than 1,000 km from one another (Fig. 1).
TEM-131–producing isolates which were indistinguishable
from one another (PFGE type A3) were found in a hospital in
Gauteng and in a hospital in the Free State. TEM-131–pro-
ducing S. enterica serotype Isangi isolates, unrelated to each
other by PFGE, were found in two different hospitals in Gau-
teng.
TEM-63–producing S. enterica serotype Isangi isolates, pos-
sibly related by PFGE (Table 2), were found in two different
hospitals in Gauteng province, while isolates of TEM-63–pro-
ducing S. enterica serotype Muenchen, indistinguishable from
one another by PFGE, were found in two different hospitals in
the Eastern Cape. The three CMY-2 producers (all different
TABLE 3. Antibiotic susceptibility (MIC values [in micrograms per
milliliter]) of the E. coli DH10B strain without (Tf) and with
(Tf) plasmid
Antibiotic(s)
E. coli
DH10B
(Tf)
E. coli DH10B (Tf) producing:
TEM-1
and
SHV-12
TEM-63 TEM-131
TEM-131
and
SHV-5
Cefotaxime 0.94 16 1.5 6 16
Cefotaxime plus,
clavulanic
acid
0.25 0.19 0.125 0.25 0.25
Ceftazidime 0.5 256 256 256 256
Ceftazidime plus
clavulanic
acid
0.25 0.75 1.5 1.5 1.5
Cefepime 0.064 4 3 2 4
Cefoxitin 4 4 4 4 4
Imipenem 0.38 0.38 0.38 0.38 0.38
Meropenem 0.023 0.032 0.032 0.032 0.032
TABLE 4. Sequence analysis of the blaTEM genes from the isolates
with phenotypic evidence of ESBL production
Enzyme
Amino acid at position:
21 104 164 182 237
TEM-1 L E R M A
TEM-63 F K S T
TEM-131 F K S T T
The one-letter amino acid code used is as follows: A, alanine; E, glutamic acid;
F, phenylalanine; K, lysine; L, leucine; M, methionine; R, arginine; S, serine; T,
threonine.
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PFGE types) were found in patients in three different hospitals
in Gauteng and in the Western Cape.
DISCUSSION
The advent of resistance of nontyphoidal Salmonella to ex-
tended-spectrum cephalosporin antibiotics is of significant
public health importance. The treatment of choice for Salmo-
nella meningitis or bacteremia in neonates is cefotaxime, and
extended-spectrum cephalosporins are widely used in the
treatment of bacteremia or osteomyelitis due to nontyphoidal
Salmonella infections in both infants and older children. We
have found that 25 of 160 (15.6%) nontyphoidal Salmonella
isolates from South Africa produced ESBLs and 3 of 160
(1.9%) produced CMY-2. Furthermore, these isolates were
frequently multiply resistant, lacking susceptibility to inexpen-
sive agents such as ampicillin, trimethoprim-sulfamethoxazole,
and chloramphenicol. Some isolates were also nalidixic acid
resistant—infections with such isolates may not respond as well
as expected to fluoroquinolones (13).
We identified TEM-63, or a novel TEM enzyme (with the
same isoelectric point), TEM-131, in S. enterica serotype
Muenchen, S. enterica serotype Isangi, and S. enterica serotype
Typhimurium isolates. According to previously published re-
ports, TEM-type beta-lactamases have been rarely found in
ESBL-producing salmonellae. The TEM-3 enzyme was found
in S. enterica serotype Typhimurium in Casablanca (1), TEM-4
was found in S. enterica serotype Mbandaka in Tunisia (28),
and a TEM-52 strain was found in a nontyphoidal Salmonella
isolate in Korea (27). It is noteworthy that TEM-63 has been
noted in several previous reports of ESBL-producing Kleb-
siella, Proteus, and Enterobacter strains in South Africa but
never previously in Salmonella strains (22). We speculate that
TEM-63 is prevalent throughout members of the Enterobacte-
riaceae family across South Africa. It is not certain to us
whether the origin of blaTEM-63 was in Salmonella spp. or
whether it originated in other organisms and was then trans-
ferred to Salmonella spp.
In all, six S. enterica serotype Isangi and three S. enterica
serotype Muenchen isolates produced the TEM-63 enzyme.
TEM-131, the novel TEM beta-lactamase, was produced by an
additional two S. enterica serotype Isangi and nine S. enterica
serotype Typhimurium strains. The sequence of TEM-63 has
four amino acid changes compared with the sequence of
TEM-1, and TEM-131 has an additional change compared to
TEM-63. This change (alanine to threonine at position 237)
also occurs in TEM-5, TEM-24, and TEM-86. Of potential
interest is that we observed somewhat higher cefotaxime MICs
for TEM-131–producing transformant strains compared to
TEM-63–producing transformant strains (Tables 3 and 5).
Ceftazidime MICs were greatly elevated (256 g/ml) for
both TEM-63– and TEM-131–producing strains.
One S. enterica serotype Isangi and seven S. enterica serotype
Typhimurium strains produced not only the novel TEM-131
enzyme but also SHV-5. Additionally, five S. enterica serotype
Typhimurium isolates produced TEM-1 and SHV-12. Al-
though SHV-5 has previously been found in South Africa (14),
SHV-12 has not. SHV-type beta-lactamases have been more
frequently found in ESBL-producing salmonellae worldwide
than TEM-type ESBLs (34). A variety of SHV-type ESBLs
have been previously noted in salmonellae (5, 6, 20, 21, 28–30,
39, 40, 43, 44, 46). Under the experimental conditions we used,
we did not find any isolates which produced a CTX-M-type
beta-lactamase, in contrast to the rising significance of these
ESBLs in Klebsiella and other species (34). CTX-M–type
TABLE 5. Antibiotic susceptibility (MIC values [in micrograms per milliliter]) of the resistant Salmonella strains
Antibiotic(s)
MIC (g/ml) for:
S. enterica serotype Isangi producing
(no. of isolates):
S. enterica serotype
Muenchen producing
(no. of isolates):
S. enterica serotype Typhimurium producing
(no. of isolates):
S. enterica
serotype
Schwarzengrund
producing
(no. of isolates):
TEM-63 (6) TEM-131(1)
TEM-131
and
SHV-5
(1)
TEM-63 (3) TEM-1 andSHV-12 (5) TEM-131 (2)
TEM-131
and SHV-5
(7)
CMY-2 (2) CMY-2 (1)
Cefotaxime 2–3 16 32 1.5–3 12–256 6 16–64 32 32
Cefotaxime and
clavulanic
acid
0.094–0.38 0.38 0.38 0.94 0.94–0.38 0.125 0.19–0.38 1 1
Ceftazidime 256 256 256 256 198–256 256 256 198–256 256
Ceftazidime and
clavulanic
acid
3–4 4 4 0.75–4 0.25–1.5 0.5 0.75–4 4 4
Cefepime 4–6 8 12 3–8 4–16 4 8–16 0.5 0.38
Cefoxitin 3–12 4 4 2 2 2 2 256 256
Imipenem 0.25 0.5 0.38 0.25–0.38 0.25–0.38 0.25–0.38 0.19–0.38 0.38 0.25
Meropenem 0.023–0.047 0.032 0.032 0.032–0.047 0.032–0.047 0.023–0.032 0.023–0.047 0.032–0.047 0.047
Nalidixic acid 256 3 4 4 3–256 4 256 4 6
Ciprofloxacin 0.094–0.125 0.012 0.012 0.012 0.08–0.25 0.008–0.012 0.19–0.25 0.012 0.012
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ESBLs have been previously found in nontyphoidal Salmonella
spp. (10).
Two S. enterica serotype Typhimurium and one S. enterica
serotype Schwarzengrund isolates produced CMY-2 beta-lac-
tamase, a beta-lactamase of the AmpC type. CMY-2–produc-
ing S. enterica serotype Typhimurium has been observed in
Taiwan (47), Romania (29), and the United States (16, 45).
More notably in North America, S. enterica serotype Newport
has been found to be a producer of CMY-2 (2, 4). However
other serovars which have been found to produce CMY-2
include S. enterica serotype Hadar (46), S. enterica serotype
Senftenberg (26, 39), S. enterica serotype Mikawasima (31),
and S. enterica serotype Montevideo (31). To our knowledge,
this is the first report of a CMY-2–producing S. enterica sero-
type Schwarzengrund strain. It is possible that use of primers
specific for CMY-2 did not allow us to detect other AmpC
beta-lactamases which may have been present in our strains.
However, with the exception of one TEM-63–producing S.
enterica serotype Isangi strain, which showed intermediate re-
sistance to cefoxitin, all other strains were cefoxitin susceptible,
making clinically significant AmpC production unlikely in
these strains.
South Africa has the highest number of human immunode-
ficiency virus (HIV)-infected people in the world, with an es-
timated 5 million infected by the virus (15). Patients with HIV
infection have an increased risk of invasive salmonellosis (11,
17–19). More than half of the isolates (59% [94 of 160]) in this
series were blood culture isolates. Given the high rate of inva-
sive infection, antibiotic resistance in Salmonella isolates in
South Africa is potentially of great clinical significance. Ampi-
cillin, trimethoprim-sulfamethoxazole, chloramphenicol, and
extended-spectrum cephalosporins are widely utilized thera-
pies for serious Salmonella infections and yet are ineffective
antibiotic options in the ESBL- and CMY-2–producing isolates
we described. Some of the isolates were also nalidixic acid
resistant, potentially limiting the effectiveness of fluoroquino-
lones. Disturbingly, we found ESBL- or CMY-2–producing
isolates in four geographically distant provinces. Our molecu-
lar epidemiologic analysis shows that some isolates in different
provinces were indistinguishable by PFGE (Table 2), indicat-
ing a common source or person-to-person spread. Preliminary
epidemiologic data suggest that the multiresistant strains ac-
tually originated in a nosocomial setting, but we speculate that
there has now been spread into the community.
We recommend that resources be utilized so that clinicians
in southern Africa can collect relevant sterile site cultures and
that clinical microbiology laboratories perform appropriate
testing for susceptibility to extended-spectrum cephalosporins.
Examples of relevant infections include neonatal Salmonella
meningitis and Salmonella bacteremia or osteomyelitis. We,
FIG. 1. Locations of the cities in which ESBL- or AmpC-producing salmonellae were obtained.
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and others, are presently investigating the clinical impact of
ESBL production by isolates that are not resistant to cefo-
taxime or ceftriaxone by conventional standards (that is, iso-
lates for which drug MICs are less than 64 g/ml).
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